(TEVA) Teva Pharma Industries - Ratings and Ratios

Tea Pharmaceutical Industries Ltd (NYSE:TEVA) is a global generics giant with a strong foothold in specialty medicines and biopharmaceuticals. Established in 1901 and headquartered in Tel Aviv, Israel, Teva operates across North America, Europe, and internationally. The company is deeply rooted in the generics space, offering a wide array of products in various dosage forms—tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also specializes in high-potency drugs, cytotoxic substances, and sterile products, catering to critical therapeutic areas like CNS (central nervous system), respiratory, and Oncology.

Tevas product portfolio is both broad and deep. They produce generic medicines combined with medical devices and offer contract manufacturing services, including active pharmaceutical ingredients (APIs). Their out-licensing platform is a strategic asset, allowing other pharmaceutical companies to access their portfolio. On the branded side, they offer notable treatments like COPAXONE for multiple sclerosis, AJOVY for migraines, and AUSTEDO for Huntingtons disease and tardive dyskinesia. Their respiratory offerings include ProAir RespiClick, QVAR for asthma, and DuoResp Spiromax, an inhaled corticosteroid combined with a long-acting beta-agonist (LABA). They also have a range of OTC products under brands like SUDOCREM and NasenDuo.

The company has built a network of collaborations with key players in the pharmaceutical industry, including MedinCell, Sanofi, and Biolojic Design Ltd. These partnerships are strategic, focusing on innovation and market expansion. Tevas financials paint a picture of a company with a market cap of ~$19.8 billion, trading at a forward P/E of 6.66 and a P/S ratio of 1.18, reflecting its valuation dynamics. With a P/B ratio of 3.65, investors should consider the balance between its asset base and market valuation. Tevas operations are a blend of generics volume and specialty medicines margin, making it a unique player in the pharmaceutical industry.